What is Scribe Therapeutics?
Scribe Therapeutics is a biotechnology enterprise dedicated to the development of next-generation CRISPR-based therapeutics. By focusing on molecular engineering, the company seeks to transform the treatment landscape for diseases that were previously considered unmanageable. Their core mission centers on the democratization of genetic medicine, ensuring that advanced therapeutic interventions are both accessible and effective. Through strategic collaborations with major pharmaceutical entities, Scribe is expanding its reach across diverse therapeutic areas, effectively bridging the gap between laboratory innovation and patient-centric clinical outcomes. The company's market position is defined by its commitment to shifting the paradigm from reactive symptom management to proactive, genetic-level disease prevention.
How much funding has Scribe Therapeutics raised?
Scribe Therapeutics has raised a total of $120M across 2 funding rounds:
Series A
$20M
Series B
$100M
Series A (2020): $20M with participation from Andreessen Horowitz
Series B (2021): $100M led by OrbiMed Advisors LLC, Andreessen Horowitz, and Avoro Capital Advisors LLC
Key Investors in Scribe Therapeutics
OrbiMed Advisors LLC
OrbiMed Advisors LLC is a premier healthcare-focused investment firm that manages capital across the entire biopharmaceutical and medical device spectrum, providing deep operational expertise to its portfolio companies.
Andreessen Horowitz
Andreessen Horowitz is a prominent venture capital firm that invests in bold entrepreneurs building the future through technology, with a significant focus on the intersection of biology and engineering.
Avoro Capital Advisors LLC
Avoro Capital Advisors LLC is an investment firm specializing in the healthcare and life sciences sectors, focusing on long-term value creation through strategic capital deployment.
What's next for Scribe Therapeutics?
With the successful closure of its latest financing round, Scribe Therapeutics is poised to scale its operational infrastructure and deepen its clinical trial initiatives. The strategic roadmap involves intensifying its molecular engineering efforts to refine the precision and safety of its CRISPR platforms. Furthermore, the company is expected to leverage its recent capital to strengthen its pharmaceutical partnerships, facilitating the transition of its lead candidates into human clinical trials. As the firm continues to mature, the focus will likely shift toward establishing long-term commercial viability and navigating the complex regulatory landscape inherent in gene-editing technologies. Investors will be closely monitoring the company's ability to translate its scientific breakthroughs into scalable, market-ready therapeutic solutions that address significant unmet medical needs.
See full Scribe Therapeutics company page
